Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis

Purpose: Ranolazine is a novel anti-angina treatment approved in the United States for chronic stable angina. Ranolazine pharmacokinetics have not been studied previously in patients who receive maintenance hemodialysis. This study describes the pharmacokinetics of ranolazine and three major metabol...

Descripción completa

Detalles Bibliográficos
Autores principales: Scoville, Bridget A., Segal, Jonathan H., Salama, Noha N., Heung, Michael, Bleske, Barry E., Eyler, Rachel F., Mueller, Bruce A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442103/
https://www.ncbi.nlm.nih.gov/pubmed/30909832
http://dx.doi.org/10.1080/0886022X.2019.1585371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442103/
https://www.ncbi.nlm.nih.gov/pubmed/30909832
http://dx.doi.org/10.1080/0886022X.2019.1585371

Ejemplares similares